Apoha Raises $36M to Commercialize Molecular Behavior Data

The big picture: London-based Apoha has raised $36M led by Singular to commercialise a platform that measures how molecules and materials actually behave, a data class that has never existed at scale before. AI has learned to read language, interpret images, and write code. It still cannot feel matter. That gap, the absence of structured, empirical data about how molecules and materials actually behave under real-world conditions, costs the pharmaceutical industry billions every year in late-stage clinical trial failures. Apoha was built to close it. And behind it is one of the more unusual founding stories in London’s deep science scene: a husband and wife, one an Oxford physicist with 15 years of foundational research, the other a Goldman Sachs Executive Director who left one of the world’s most powerful financial institutions to help turn that research into a commercial platform.

Why it matters:

• Costly failures: The pharmaceutical industry loses billions annually due to late-stage clinical trial failures, often stemming from a lack of empirical data on how molecules behave in real-world conditions.
• Market growth: The global biophysical assays market, which Apoha’s technology addresses, is projected to grow from $3.8B in 2025 to $7.9B by 2034, at an 8.5% CAGR.
• AI’s blind spot: While AI excels at language and image interpretation, it lacks the ability to ‘feel’ matter, leaving a critical gap in understanding molecular behavior that Apoha aims to fill with its novel data layer.

How it works:

• VIBE® assay: Apoha’s VIBE® assay takes a sample smaller than a pinhead, suspends it in liquid, applies controlled stresses, and captures wave patterns, producing over 1,000 simultaneous behavioral descriptors in minutes.
• High precision: Joint research with Boehringer Ingelheim demonstrates Apoha identifying high-risk antibody candidates with over 90% precision from just 8 micrograms of material, outperforming 12 industry-standard tests.
• Early detection: The platform provides a single readout that can predict whether a drug candidate will fail before it reaches clinical trials, potentially saving large multi-site customers $100M or more.

The catch: Apoha operates in a market with existing contract biophysics providers like Malvern Panalytical and Charles River Laboratories, which perform individual tests but lack Apoha’s simultaneous multi-descriptor profiling. Scientific data platforms such as Dotmatics manage experimental data but do not generate the behavioral layer Apoha produces. The company’s success hinges on its ability to scale this technically complex data layer and establish it as a foundational component for physical-world AI applications before better-capitalized rivals develop similar capabilities.